BidaskClub upgraded shares of Kindred Biosciences (NASDAQ:KIN) from a strong sell rating to a sell rating in a research note published on Saturday, BidAskClub reports.

Several other equities analysts have also commented on KIN. Barclays reaffirmed a hold rating on shares of Bank of Montreal in a research report on Tuesday, June 11th. Guggenheim reiterated a buy rating and issued a $95.00 price target (up previously from $90.00) on shares of VF in a report on Thursday, May 23rd. ValuEngine downgraded shares of Zynerba Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, July 17th. Cantor Fitzgerald set a $135.00 price target on shares of Zimmer Biomet and gave the stock a buy rating in a report on Friday, April 26th. Finally, Stifel Nicolaus set a $154.00 price target on shares of argenx and gave the stock a buy rating in a report on Wednesday, May 22nd. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and seven have issued a buy rating to the stock. The company currently has an average rating of Buy and an average price target of $14.28.

Shares of Kindred Biosciences stock opened at $6.87 on Friday. The company has a quick ratio of 8.70, a current ratio of 9.10 and a debt-to-equity ratio of 0.01. The firm has a 50 day moving average of $7.72. Kindred Biosciences has a 52 week low of $5.96 and a 52 week high of $15.75.

Kindred Biosciences (NASDAQ:KIN) last announced its quarterly earnings data on Thursday, May 9th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.41) by ($0.01). The company had revenue of $0.52 million for the quarter, compared to analysts’ expectations of $1.95 million. Analysts expect that Kindred Biosciences will post -1.45 EPS for the current fiscal year.

Large investors have recently modified their holdings of the stock. Marshall Wace LLP acquired a new position in Kindred Biosciences in the 1st quarter worth approximately $53,000. BNP Paribas Arbitrage SA increased its holdings in Kindred Biosciences by 83,433.3% in the 1st quarter. BNP Paribas Arbitrage SA now owns 7,518 shares of the biopharmaceutical company’s stock worth $69,000 after buying an additional 7,509 shares during the period. Metropolitan Life Insurance Co. NY increased its holdings in Kindred Biosciences by 362.9% in the 4th quarter. Metropolitan Life Insurance Co. NY now owns 9,647 shares of the biopharmaceutical company’s stock worth $106,000 after buying an additional 7,563 shares during the period. Meeder Asset Management Inc. increased its holdings in Kindred Biosciences by 16.7% in the 1st quarter. Meeder Asset Management Inc. now owns 11,922 shares of the biopharmaceutical company’s stock worth $109,000 after buying an additional 1,706 shares during the period. Finally, Teton Advisors Inc. increased its holdings in Kindred Biosciences by 30.8% in the 1st quarter. Teton Advisors Inc. now owns 17,000 shares of the biopharmaceutical company’s stock worth $156,000 after buying an additional 4,000 shares during the period. Institutional investors own 65.14% of the company’s stock.

About Kindred Biosciences

Kindred Biosciences, Inc, a commercial-stage biopharmaceutical company, focusing on developing therapies for pets. Its product pipeline consists of small molecules and biologics for a range of indications in dogs, cats, and horses. The company offers Mirataz, a mirtazapine transdermal ointment for the management of weight loss in cats.

Featured Article: What is systematic risk?

Analyst Recommendations for Kindred Biosciences (NASDAQ:KIN)

Receive News & Ratings for Kindred Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kindred Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.